The impact of the AB0 and the Rhesus blood group system on outcomes in bladder cancer patients treated with radical cystectomy

World Journal of Urology
Oliver EngelMichael Rink

Abstract

To investigate the impact of the AB0 and the Rhesus blood group system on outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). We included 511 UCB patients treated with RC without neoadjuvant chemotherapy from 1996 to 2011 at our institution. Cox and logistic regression models assessed the association of the AB0 blood group antigen and Rhesus factor expression with tumor biologic features and outcomes, respectively. In total, 216 patients (42.3 %) had the blood group antigen A0, 73 patients (14.3 %) the antigen B0, 33 patients (6.4 %) the antigen AB and 189 patients (37.0 %) the antigen 00. In addition, 414 patients (81.0 %) were Rhesus factor positive. The AB0 blood group antigen expression was associated with a higher tumor grade (p = 0.003). In contrast, the Rhesus factor was not associated with any clinicopathologic characteristics. Neither the AB0 blood group antigens nor the Rhesus factor was associated with survival. In a sensitivity analysis of patients receiving adjuvant chemotherapy, however, the blood group antigen AB expression was associated with reduced cancer-specific and overall survival. The AB0 blood group antigens and the Rhesus factor are not associated with su...Continue Reading

References

Jan 1, 1988·Scandinavian Journal of Urology and Nephrology·P U MalmströmB Andersson
Jun 20, 2002·Journal of Cancer Research and Clinical Oncology·Hanne PrimdahlTorben F Ørntoft
Aug 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yair LotanArthur I Sagalowsky
Dec 3, 2009·Cellular and Molecular Life Sciences : CMLS·Cheng-Han Huang, Mao Ye
Sep 14, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Simona IodiceAlbert B Lowenfels
Jun 28, 2011·European Journal of Gastroenterology & Hepatology·Christine P J CaygillKarna Dev Bardhan
Feb 23, 2012·Current Urology Reports·Michael RinkShahrokh F Shariat
Jul 31, 2012·BMC Cancer·Nuh N RahbariJürgen Weitz
Sep 4, 2012·BJU International·Michael RinkUNKNOWN Bladder Cancer Research Consortium
Sep 11, 2012·BJU International·Samuel D KaffenbergerPeter E Clark
May 8, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Massimo Franchini, Giancarlo Maria Liumbruno
Jul 28, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Dilek UnalBunyamin Kaplan
Dec 18, 2013·The Journal of Urology·Tobias KlatteShahrokh F Shariat
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Mar 29, 2014·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·A SoaveM Rink
Mar 29, 2014·International Urology and Nephrology·Evren SüerYaşar Bedük
May 28, 2014·Human Molecular Genetics·Thorunn RafnarKari Stefansson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.